TriangleNCT02113982 · CITED IN SOURCE DOCUMENTS
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE1, PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2024-08-01
This is a 4-stage, non-randomized, open-label, dose escalation and expansion, multicenter study. A cycle of therapy is 21 days. Stage 1 was a dose-escalation stage. During Stages 2-4, patients are treated at the MTD or maximum tested dose at which multiple DLTs are not observed during Stage 1.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
MTD (Stage 1)
CR Rate in First-line BPDCN (Stage 3, Pivotal Cohort)
CR Rate in First-line BPDCN, R/R BPDCN and AML
Duration of CR in First-line BPDCN, R/R BPDCN and AML
ORR in First-line BPDCN, R/R BPDCN and AML
OS in First-line BPDCN, R/R BPDCN and AML
Bridge to SCT in First-line BPDCN, R/R BPDCN and AML
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. The patient has a diagnosis of AML (Protocol Stages 1 and 2) or BPDCN (Protocol Stages 1-4) according to WHO classification (AML; excluding acute promyelocytic leukemia \[APL, FAB M3\]) or confirmed by hematopathology (BPDCN) (Facchetti et al. 2008). 2. The patient must meet one of the following (a) or (b) or (c): 1. Has evidence of persistent or recurrent AML (Protocol Stages 1 and 2) in the peripheral blood and/or bone marrow that is refractory to, or has relapsed from, their most recent prior line of treatment. * A prior line of treatment is considered an induction regimen if it involves an approved or investigational cytotoxic chemotherapy agent, biological agent, and/or hypomethylating agent administered alone or in a combination regimen, with the intent to induce robust cytoreduction (i.e., CR). * The previous induction regimen may have been a SCT with intent to induce a CR. * Consolidation and/or maintenance (including SCT) may have been given in CR/CRi, but are not counted as a line of treatment. * Hydroxyurea will not be considered a prior line of treatment. 2. Has previously untreated AML (Protocol Stages 1 and 2) and is considered to be at high risk for disease progression and/or is unlikely to derive more than transient benefit from standard therapy by having at least one of the following: * Treatment-related AML, except if it is associated with favorable cytogenetics (e.g., inversion 16, t\[16;16\], t\[8;21\], t\[15;17\]), and not a candidate for SCT in their current disease state. * AML with antecedent hematological disease (e.g., MDS, myelofibrosis, polycythemia vera) and not a candidate for SCT. 3. Has histological and/or cytological evidence of BPDCN by pathologic assessment at the investigative site according to WHO classification (Facchetti et al. 2008) by a pathologist with expertise in hematologic malignancies, that can be measured for treatment response and is either: * Previously untreated (i.e., first-line) (Protocol Stages 2-4). * Persistent or recurrent in the peripheral blood, bone marrow, spleen, lymph nodes, skin, or other sites after previous treatment with at least 1 line of systemic therapy for BPDCN, e.g., stem cell transplant or chemotherapy (Protocol Stages 1, 2, and 4). A pathology specimen must be available for central pathology review for all BPDCN patients enrolled in Protocol Stages 2-4. 3. The patient is ≥ 18 years old. 4. The patient has an ECOG performance score (PS) of 0-2. 5. The patient has adequate baseline organ function, including cardiac, renal, and hepatic function: * Left ventricular ejection fraction (LVEF) ≥ institutional lower limit of normal as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECG * Serum creatinine ≤ 1.5 mg/dl * Serum albumin ≥ 3.2 g/dl * Bilirubin ≤ 1.5 mg/dl * AST and ALT ≤ 2.5 times the upper limit of normal (ULN) 6. If the patient is a woman of child bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 1 week prior to treatment. 7. The patient has signed informed consent prior to initiation of any study-specific procedures or treatment. 8. The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment. 9. The patient (male and female) agrees to use acceptable contraceptive methods for the duration of time on the study, and continue to use acceptable contraceptive methods for 2 months after the last infusion of Tagraxofusp. Exclusion Criteria: 1. The patient has a diagnosis of acute promyelocytic leukemia (APL; FAB M3). 2. The patient has persistent clinically significant toxicities Grade ≥ 2 from previous chemotherapy (excluding alopecia, nausea, fatigue, and liver function tests (as mandated in the inclusion criteria)). 3. The patient has received treatment with chemotherapy, wide-field radiation, or biologic therapy within 14 days of study entry. 4. The patient has received treatment with another investigational agent within 14 days of study entry. 5. The patient has previously received treatment with Tagraxofusp. 6. The patient has an active malignancy and/or cancer history (excluding AML, BPDCN, or antecedent MDS) that may confound the assessment of the study endpoints. Patients with a past cancer history (within 2 years of entry) with substantial potential for recurrence and/or ongoing active malignancy must be discussed with the Sponsor before study entry. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, cervical intraepithelial neoplasia, organ-confined prostate cancer with no evidence of progressive disease. 7. The patient has clinically significant cardiovascular disease (e.g., uncontrolled or any NYHA Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction or stroke within 6 months of study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication). 8. The patient has uncontrolled, clinically significant pulmonary disease (e.g., COPD, pulmonary hypertension) that in the opinion of the investigator would put the patient at significant risk for pulmonary complications during the study. 9. The patient has known active or suspected CNS leukemia. If suspected, CNS leukemia should be ruled out with relevant imaging and/or examination of cerebrospinal fluid. 10. The patient is receiving immunosuppressive therapy - with the exception of low-dose prednisone (≤ 10 mg/day) - for treatment or prophylaxis of graft-versus-host disease (GVHD). If the patient has been on immunosuppressive treatment or prophylaxis for GVHD, the treatment(s) must have been discontinued at least 14 days prior to study treatment and there must be no evidence of Grade ≥ 2 GVHD. 11. The patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, DIC, or psychiatric illness/social situations that would limit compliance with study requirements. 12. The patient is pregnant or breast feeding. 13. The patient has known positive status for human immunodeficiency virus (HIV) active or chronic Hepatitis B or Hepatitis C. 14. The patient is oxygen-dependent. 15. The patient has any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Intervention: Tagraxofusp
- intervention Names
- Drug: Tagraxofusp
- label
- First-Line Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- type
- EXPERIMENTAL
- description
- Intervention: Tagraxofusp
- intervention Names
- Drug: Tagraxofusp
- label
- Relapse/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- type
- EXPERIMENTAL
- description
- Intervention: Tagraxofusp
- intervention Names
- Drug: Tagraxofusp
- label
- Acute Myeloid Leukemia
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Acute Myeloid Leukemia
- First-Line Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Relapse/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- name
- Tagraxofusp
- other Names
- SL-401
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 138
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Maximum tolerated dose (MTD) in both patients with BPDCN and AML. MTD defined as the highest dose level where less than 2/3 or 2/6 patients experienced a DLT
- measure
- MTD (Stage 1)
- time Frame
- 21-day period after the first dose (cycle 1)
- description
- Complete response (CR) rate, defined as the percentage who achieved CR+ CR(clinical) with minimal residual skin abnormality (CRc) after treatment with Tagraxofusp. CR criteria according to Cheson BD et al, The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586: Marrow: normalization of blast percentage (≤5%). Peripheral blood: normalization of neutrophil count (≥ 1,000/µL) and platelet count (≥ 100,000/µL) - absence of leukemic blasts Skin: 100% clearance of all skin lesions from baseline; no new lesions in patients without lesions at baseline Nodal masses: regression to normal size on CT Spleen, liver: not palpable, nodules disappeared CRc criteria: all the above except for skin: marked clearance of all skin lesions from baseline; residual hyperpigmentation or abnormality with BPDCN identified on biopsy (or no biopsy performed)
- measure
- CR Rate in First-line BPDCN (Stage 3, Pivotal Cohort)
- time Frame
- at pre-defined treatment cycle intervals from randomization up to disease progression, up to 3.5 years
- secondary Outcomes
- description
- CR rate, defined as the percentage of patients who achieved CR+ CR with minimal residual skin abnormality (CRc) after treatment with Tagraxofusp. CR criteria according to Cheson BD et al, The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586: Marrow: normalization of blast percentage (≤5%) Peripheral blood: normalization of neutrophil count (≥ 1,000/µL) and platelet count (≥ 100,000/µL) - absence of leukemic blasts Skin: 100% clearance of all skin lesions from baseline; no new lesions in patients without lesions at baseline Nodal masses: regression to normal size on CT Spleen, liver: not palpable, nodules disappeared CRc criteria: all the above except for skin: marked clearance of all skin lesions from baseline; residual hyperpigmentation or abnormality with BPDCN identified on biopsy (or no biopsy performed)
- measure
- CR Rate in First-line BPDCN, R/R BPDCN and AML
- time Frame
- at pre-defined treatment cycle intervals from randomization up to disease progression, up to 5 years
- description
- Duration of complete response (CR) defined as the time from when the criteria are first met for CR+CRc (whichever was recorded first) until the date that the criteria for relapse after CR+CRc are met, according to the previously reported criteria for CR and CRc and following criteria of relapse after CR+CRc (Cheson BD et al. J Clin Oncol 2007;25:579-586.): Marrow: blast percentage \>5% (if no peripheral blasts, then confirmation aspirate required ≥ 1week later) Peripheral blood: presence of leukemic blasts Skin: increase in skin score greater than the sum of nadir plus 50% baseline score Nodal masses: appearance of a new lesion(s) \>1.5 cm in any axis, ≥50% increase from nadir in SPD of more than one node, or ≥50% increase from nadir in longest diameter of a previously identified node \>1cm in short axis Spleen, liver: \>50% increase from nadir in the SPD of any previous lesions
- measure
- Duration of CR in First-line BPDCN, R/R BPDCN and AML
- time Frame
- at pre-defined treatment cycle intervals from randomization up to disease progression, up to 5 years
- description
- Objective response rate (ORR) defines as the percentage of patients who achieved CR (CR+CRc), CR with incomplete blood count recovery (CRi), or partial response (PR) after treatment with Tagraxofusp according to the previously reported definitions of CR, CRc and the following one of CRi and PR: CRi: CR with incomplete of neutrophil and/or platelet count and absence of leukemic blast in the peripheral blood Marrow: PR defined as decrease by ≥50% in blast percentage to 5-25% Peripheral blood: PR defined as normalization of neutrophil count (≥ 1,000/µL) and platelet count (≥ 100,000/µL) Skin: 50%-\<100% clearance of all skis lesions from baseline; no new lesions in patients without lesions at baseline Nodal masses: ≥50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes Spleen, liver: ≥50% in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen
- measure
- ORR in First-line BPDCN, R/R BPDCN and AML
- time Frame
- at pre-defined treatment cycle intervals from randomization up to disease progression, up to 5 years
- description
- Overall survival (months) defined as the time from the date of first infusion of Tagraxofusp to the date of death from any cause
- measure
- OS in First-line BPDCN, R/R BPDCN and AML
- time Frame
- From first infusion to treatment discontinuation when survival is assessed every 90 days up to end of follow-up or death, up to 5 years
- description
- Bridge to Stem Cell Transplant (SCT) defined as the percentage of patients who received SCT subsequent to achieving an Investigator-determined outcome from Tagraxofusp that was deemed by the Investigator to enable an SCT
- measure
- Bridge to SCT in First-line BPDCN, R/R BPDCN and AML
- time Frame
- at pre-defined intervals up to achievement of outcome enabling an SCT for a period, up to 5 years
Full study description
- brief Summary
- This is a 4-stage, non-randomized, open-label, dose escalation and expansion, multicenter study. A cycle of therapy is 21 days. Stage 1 was a dose-escalation stage. During Stages 2-4, patients are treated at the MTD or maximum tested dose at which multiple DLTs are not observed during Stage 1.
- detailed Description
- Study 0114 is a multi-stage, non-randomized, open-label, multicenter study of Tagraxofusp in First line and Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and Acute Myeloid Leukemia (AML) patients divided into 4 stages. Each study stage has its own unique objectives and patient population, with Stage 1 representing the dose escalation phase and Stage 3 the pivotal phase. In Stages 1 and 2, both patients with BPDCN (first-line and R/R) and AML were enrolled; Stage 3 enrolled previously untreated (first-line) BPDCN patients only. A separate stage, Stage 4, enrolled First-line and R/R BPDCN patients to further characterize safety and efficacy of Tagraxofusp. The primary study objectives are reported below by stage: Stage 1: to determine the Maximum Tolerated Dose (MTD) (or Maximum Tested Dose, MTeD where multiple DLTs were not observed) of Tagraxofusp administered at the following dose levels 7, 9, 12, 16 µg/kg/day Stage 2: cohort expansion to determine the efficacy and safety of Tagraxofusp at the MTD selected in Stage 1 Stage 3 (pivotal): to determine the efficacy and safety of Tagraxofusp in patients with First-line BPDCN Stage 4: to further characterize the efficacy and safety of Tagraxofusp in patients with both First-line and R/R BPDCN
Source references
- references
- citation
- Konopleva M, Pemmaraju N, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat T, Zuurman M, Gupta I, Lane AA. Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm. Cancer. 2026 Jan 1;132(1):e70243. doi: 10.1002/cncr.70243.
- pmid
- 41486505
- type
- DERIVED
- citation
- Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. doi: 10.1200/JCO.22.00034. Epub 2022 Jul 12.
- pmid
- 35820082
- type
- DERIVED
- citation
- Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.
- pmid
- 31018069
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-688f0faeb7f6bf11eca1
- requested nct id
- NCT02113982
- primary nct id
- NCT02113982
- source kind
- fda_spl_label
- source record id
- f219a6c1-2e94-40a7-8b66-28520f7bb7f7
- source file sha256
- 8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7
- payload sha256
- db2cb708707822d853415d9665d747804a5ab45cb478dd664a40367c7d945d2e
- payload
- application numbers
- BLA761116
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-688f0faeb7f6bf11eca1
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02113982
- occurrences
- context exact
- on of follow up (months) Median 11.5 Minimum, Maximum 0.2, 12.7 14.2 Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) STML-401-0114 (NCT02113982; Study 0114) was a multicenter, open-label, single-arm, clinical trial that included 15 patients with relapsed or refractory BPDCN. Treatment consisted of ELZO
- end
- 1541
- exact text
- NCT02113982
- start
- 1530
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00800.json
- source file sha256
- 8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7
- source json pointer
- /results/3/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- f219a6c1-2e94-40a7-8b66-28520f7bb7f7
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 13e993cf5a53bd7947525808efc97f1e2ceff0a69d361d7bc35454950ea9caa9
- spl effective time
- 20241209
- spl set id
- 80eb1080-fe20-4af0-b2a5-a67999923fa8
Preserved source evidence · Not medical advice